Dogwood Therapeutics, Inc. 8-K

What Happened

• On March 18, 2026, Dogwood Therapeutics, Inc. (DWTX) filed a Form 8-K (Item 2.02) and issued a press release announcing its results of operations for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1 to the 8-K. The report was signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer.

Key Details

• Filing date: March 18, 2026 (Form 8-K, Item 2.02).
• Reporting period: fourth quarter and full year ended December 31, 2025.
• Press release: furnished as Exhibit 99.1 to the Form 8-K.
• Corporate officer signing the filing: Angela Walsh, CFO, Corporate Secretary and Treasurer.

Why It Matters

• This filing notifies investors that Dogwood has publicly released its quarterly and annual operating results; investors should read the press release and the company’s subsequent SEC filings for the detailed financial metrics (revenues, operating results, cash position, and any management commentary or guidance).
• Timely review of the disclosed results can affect short-term trading decisions and longer-term assessments of the company’s financial health and progress toward clinical or commercial milestones.